Q&A with Dan Woods, CEO of El Camino Hospital

We have been looking forward to sitting down with the new CEO of long-time Fogarty Institute partner El Camino Hospital, which provides a forum where innovators can work directly with experienced, recognized physicians and conduct clinical trials, as four companies-in-residence currently are doing. Dan Woods joined the hospital in the fall of 2017, bringing an entrepreneurial spirit,

nVision’s Acquisition Positions Innovative Technology to Potentially Help Millions of Women

As the first and only device cleared by the FDA to collect cells from the fallopian tubes, the Mako 7 device, originally developed by nVision, a Fogarty Institute graduate, offers a potential platform for earlier detection of ovarian cancer. The company was recently acquired by Boston Scientific, as the device represents an exciting opportunity for the company to expand its focus on women’s health and provides a potential platform to improve care for women worldwide.

The One Clear Message from the FDA? “We are Here to Help”

Navigating through the Food and Drug Administration’s (FDA) policies, laws, pathways to approval and potential changes to existing regulations can be an intimidating process, especially for new or early-stage medical device startups. However, the organization has done an admirable job at proactively developing educational programs and reaching out to the industry and consumers.

START TYPING AND PRESS ENTER TO SEARCH